Medigene reports Phase I/II data for prostate cancer vaccine

Medigene AG (Xetra:MDG1) said none of five high-risk prostate cancer patients who underwent radical

Read the full 147 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE